ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe (ACCESS-EU)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Evalve
ClinicalTrials.gov Identifier:
NCT01288976
First received: January 25, 2011
Last updated: March 6, 2014
Last verified: March 2014

January 25, 2011
March 6, 2014
October 2008
June 2012   (final data collection date for primary outcome measure)
  • Change from Baseline in Quality of Life at 12-month follow-up. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Minnesota Living with Heart Failure Questionnaire will be used as a measure of the patients' perceptions of the effects of congestive heart failure on their lives.
  • Change from baseline in 6-minute walk distance test at 12 months. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The 6-minute walk distance test will be used to measure the patient's exercise capacity.
  • Change from Baseline in Quality of Life at 12-month follow-up. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Minnesota Living with Heart Failure Questionnaire will be used as a meaure of the patients' perceptions of the effects of congestive heart failure on their lives.
  • Change from baseline in 6-minute walk distance test at 12 months. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The 6-minute walk distance test will be used to measure the patient's exerice capacity.
  • Change from baseline in TTE core-lab assessed MR at 12-months. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Trans-thoracic echocardiography data will assessed by a Core Lab to assess mitral regurgitation.
Complete list of historical versions of study NCT01288976 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe
ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe

The MitraClip System enables the European physicians an alternative therapeutic option for patients with mitral regurgitation (MR). Therapeutic alternatives are open-heart cardiac surgery, and palliative medical therapy with or without device therapy. The study will observe the outcomes of patients treated with the MitraClip System throughout 12-months as compared to the outcomes of patients treated by alternative therapies.

PHASE I:

The primary objective of ACCESS-EU Phase I is to gain information in the European Union Countries regarding the use of the MitraClip System with respect to health economics and clinical care.

PHASE II: (HAS BEEN CLOSED BY SPONSOR) The primary objective of ACCESS-EU Phase II is to gather additional clinical data, specifically Echocardiography Core Laboratory measurements of MR severity and left ventricular volumes and diameters, and other echocardiographic measures, on patients undergoing the MitraClip procedure in the European Union Countries,

Clinical data collected from both study phases, is expected to contribute to decision making with regards to MitraClip therapy selection in patients with MR: (a) by establishing the value of the MitraClip therapy in the continuum of care; and (b) by providing practical information that will allow physicians to make therapeutic decisions, assist hospitals to make purchasing decisions, and assist insurers in making coverage decisions.

Study Design:

ACCESS-Europe is a two-phase prospective, observational, multicenter post-approval study of the MitraClip System for the treatment of mitral regurgitation (MR) in the European Union Countries. Patients will be evaluated per standard practice at baseline, discharge, 6-Months and 12-Months.

Phase I of the study consists of patients who receive the MitraClip system for the treatment of MR and two concurrent comparator groups of (a) medically managed heart failure patients with MR and (b) patients who have undergone mitral valve surgery for MR. The two comparator groups will be followed and evaluated primarily from a health economic perspective.

ACCESS EU Study Phase II will consist of only patients who receive the MitraClip System, with the objective to collect additional clinical data, specifically Echocardiography Core Laboratory evaluation of MR severity and other echocardiographic measures.

Enrollment of patients in each study phase is as follows:

ACCESS-EU PHASE I:

  • A minimum of 300 MitraClip Therapy group patients,
  • A minimum of 100 patients in the Mitral Valve Surgery comparator group
  • As many patients as possible in the Medical Therapy comparator group

First Patient Enrollment Projection: Q1, 2009 Last Patient Enrollment Projection: Enrollment in the Mitral Valve Surgery and Medically Therapy groups ceased on December 31, 2010. Enrollment in the MitraClip group will cease when Phase II of the study is initiated at each site.

ACCESS-EU PHASE II:

A minimum of 300 MitraClip therapy subjects will be enrolled in Phase II.

First Patient Enrollment Projection: Q2, 2011 Last Patient Enrollment Projection: Enrollment will cease when the Sponsor has determined that an adequate number of patients have been enrolled.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients with Mitral Regurgitation

Mitral Valve (MV) Regurgitation
  • Device: MitraClip
    The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
  • Drug: Medical Management
    The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
  • Procedure: Mitral Valve Surgery
    The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
  • MitraClip Therapy
    Patients treated with the MitraClip System.
    Intervention: Device: MitraClip
  • Medical Management
    Patients with MR managed non-surgically based on standard hospital clinical practice.
    Intervention: Drug: Medical Management
  • Mitral Valve Surgery
    Patients with MR managed surgically (repair or replacement) based on standard hospital clinical practice.
    Intervention: Procedure: Mitral Valve Surgery

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
567
August 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Per the current approved labeling for the Conformity European (CE) Marked MitraClip System.

Exclusion Criteria:

  • Per the current approved labeling for the CE Marked MitraClip System.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01288976
EU-0901
No
Evalve
Evalve
Not Provided
Study Director: Barathi Sethuraman, PhD Abbott Vascular Structural Heart (Evalve Inc)
Principal Investigator: Wolfgang Schillinger, MD Universitatsmedizin Gottingen
Principal Investigator: Francesco Maisano, MD Fondazion Ctr San Raffaele Del Monte Tabor Istituto
Evalve
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP